About: EFPIA
EU cancer plan ushers in ‘new era’ for preventing, tackling cancer
Stakeholders in the health sector widely welcomed the long-awaited Europe's Beating Cancer Plan, unveiled on Wednesday (3 January), as a "new era for cancer care and cancer patients" which places the European Union at the forefront of research and innovation efforts.Transparency in the race for a COVID vaccine
As the coronavirus crisis continues to have a devasting impact on people’s lives and livelihoods, all eyes are on scientists to deliver on a COVID-19 vaccine. It is widely accepted that a safe and effective vaccine represents our best chance...Commission announces funding for COVID-19 diagnosis, treatment projects
The European Commission announced on Tuesday (12 May) that eight research projects aimed at developing treatments and diagnostics for the coronavirus have been selected for funding in a fast-track call for proposals.Pharma boss: EU will have to focus on long-term medical research ecosystem
After the coronavirus crisis is over, Europe will need policies that can create a research ecosystem in the long run as well as ensure access to medicines to the patients who need them in a way that is sustainable for health systems today and tomorrow, a leading representative of European pharmaceuticals told EURACTIV in an interview.Better access to health innovation is Kyriakides’ top priority (and hardest task)
With increased powers, Health Commissioner-designate Stella Kyriakides is tasked with striking a difficult balance between making sure there is a steady supply of affordable medicines and ensuring that EU pharma industry remains a world leader in innovation.New pharma boss: Next EU Commission should be clear on how to protect innovation
The next EU Commission should take a stronger position on innovation in the pharma sector, the new leader of the European Federation of Pharmaceutical Industries and Associations (EFPIA) told EURACTIV.com in an interview.Pharma industry raises the alarm about stockpiling of generic drugs
The industry of innovative medicines is concerned with a recent vote in the European Parliament on the stockpiling of generic drugs, saying that it causes uncertainty over innovation in the pharmaceutical field.Discussion heats up over stockpiling of generic drugs under patent protection
The Commission has announced its intention to add a manufacturing waiver to supplementary protection certificates (SPC), as part of its upgraded 2015 Single Market Strategy.Protecting the spark, avoiding the storm
Every new treatment, every transformational shift in the outlook for patients starts with the spark of an idea, writes Nathalie Moll.